209 related articles for article (PubMed ID: 15899075)
1. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
Montemurro F; Aglietta M
Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
[TBL] [Abstract][Full Text] [Related]
2. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
6. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Sánchez-Muñoz A; García-Tapiador AM; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Martínez-Ortega E; Fernández Morales M; Fernández-Navarro M; de la Torre Cabrera C; Dueñas B; Ureña C; Martínez J; Morales F; Ramírez-Tortosa C; Sánchez-Rovira P
Breast J; 2008; 14(5):506-7. PubMed ID: 18705667
[No Abstract] [Full Text] [Related]
9. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
[TBL] [Abstract][Full Text] [Related]
10. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Fornier M; Esteva FJ; Seidman AD
Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
14. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
Lazaridis G; Pentheroudakis G; Pavlidis N
Crit Rev Oncol Hematol; 2008 Apr; 66(1):31-41. PubMed ID: 17766143
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
16. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
Puglisi F; de Azambuja E; de Castro G; Demonty G
J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195
[No Abstract] [Full Text] [Related]
17. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
18. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
